

GLAXOSMITHKLINE PLC

Form 6-K

April 12, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 12 April 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
Chief Executive Officer
- b) Position/status

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.

- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| £15.7582                 | 23        |
| n/a (single transaction) |           |

Aggregated information

- d) Aggregated volume  
Price

- e) Date of the transaction 2019-04-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Vaccines

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793  
Details of the transaction(s): section to be repeated for (i) each type of  
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882  
b) Nature of the transaction Acquisition of Ordinary  
Shares following the  
re-investment of dividends  
paid to shareholders on 11  
April 2019, on shares held  
through the Company's Share  
Reward Plan.  
c) Price(s) and volume(s) Price(s) Volume(s)  
£15.7582 77  
n/a (single transaction)

Aggregated information

- d) Aggregated volume  
Price  
e) Date of the transaction 2019-04-11  
f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S Dingemans  
b) Position/status Executive Director  
c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793  
Details of the transaction(s): section to be repeated for (i) each type of  
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882  
b) Nature of the transaction Acquisition of Ordinary  
Shares following the

re-investment of dividends  
paid to shareholders on 11  
April 2019, on shares held  
through the Company's Share  
Reward Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7582	29
	n/a (single transaction)	

Aggregated information

d) Aggregated volume  
Price

e) Date of the transaction	2019-04-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr N Hiron
b) Position/status	SVP, Global Ethics & Compliance

c) Initial notification/ amendment	Initial notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of  
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	---

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
------------------------------	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.7582	14

d) Aggregated information	n/a (single transaction)
---------------------------	--------------------------

Aggregated volume  
Price

e) Date of the transaction 2019-04-11  
f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms S Jackson  
SVP, Global  
b) Position/status Communications and CEO  
Office

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary  
Shares following the  
re-investment of dividends  
paid to shareholders on 11  
April 2019, on shares held  
through the Company's Share  
Reward Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
£15.7582 71

Aggregated information

n/a (single transaction)

d) Aggregated volume  
Price

e) Date of the transaction 2019-04-11  
f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D Jackson  
PCA of Ms S Jackson (SVP,  
Global Communications and  
CEO Office)
  - b) Position/status
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary  
Shares following the  
re-investment of dividends  
paid to shareholders on 11  
April 2019, on shares held  
through the Company's Share  
Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.7582	23

 Aggregated information  
n/a (single transaction)
  - d) Aggregated volume  
Price
  - e) Date of the transaction 2019-04-11
  - f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr L Miels  
President, Global  
Pharmaceuticals
  - b) Position/status
  - c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.7582	4
n/a (single transaction)	
  - d) Aggregated information
 

Aggregated volume	
Price	
  - e) Date of the transaction 2019-04-11
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D S Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.						
c)	Price(s) and volume(s)	<table border="0"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">£15.7582</td> <td style="text-align: right;">87</td> </tr> <tr> <td colspan="2">n/a (single transaction)</td> </tr> </table>	Price(s)	Volume(s)	£15.7582	87	n/a (single transaction)	
Price(s)	Volume(s)							
£15.7582	87							
n/a (single transaction)								

Aggregated information

d)	Aggregated volume Price	
e)	Date of the transaction	2019-04-11
f)	Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr R Simard
b)	Position/status	President, Pharma Supply Chain
c)	Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	<p>Ordinary shares of 25 pence each ('Ordinary Shares')</p> <p>ISIN: GB0009252882</p>
----	---	---

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.				
c)	Price(s) and volume(s)	<table border="0"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">£15.7582</td> <td style="text-align: right;">23</td> </tr> </table>	Price(s)	Volume(s)	£15.7582	23
Price(s)	Volume(s)					
£15.7582	23					
d)	Aggregated information	n/a (single transaction)				



Aggregated volume  
Price

- e) Date of the transaction 2019-04-11  
f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882						
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.						
c) Price(s) and volume(s)	<table border="0"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">£15.7582</td> <td style="text-align: right;">87</td> </tr> <tr> <td colspan="2">n/a (single transaction)</td> </tr> </table>	Price(s)	Volume(s)	£15.7582	87	n/a (single transaction)	
Price(s)	Volume(s)						
£15.7582	87						
n/a (single transaction)							

Aggregated information

- d) Aggregated volume  
Price
- e) Date of the transaction 2019-04-11  
f) Place of the transaction London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr P C Thomson
  - b) Position/status President, Global Affairs
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.7582	50
n/a (single transaction)	
  - d) Aggregated information
 

Aggregated volume	Price
  - e) Date of the transaction 2019-04-11
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mrs V A Whyte
  - b) Position/status Company Secretary
  - c) Initial notification/  
amendment Initial notification
- 2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type

3. of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.

- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£15.7582 63

n/a (single transaction)

Aggregated information

- d) Aggregated volume  
Price

- e) Date of the transaction 2019-04-11  
f) Place of the transaction London Stock Exchange (XLON)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 12, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc